Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandip Basu

Showing results (91-100 of 519) with videos related to

Pageof 52
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|April 20, 2016
Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?Bhakti Basu, Sandip Basu
Journal of Nuclear Medicine Technology|April 20, 2022
Metachronous Adenocarcinoma of the Lung in the Setting of Metastatic Gastric Neuroendocrine Tumor: Value of Elucidating Discordance on Dual-Tracer PET/CT with Ki-67 IndexSarvesh Loharkar, Sandip Basu
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 5, 2019
Leveraging the power of non-radium radionuclide treatments in bone metastasesPradeep Thapa, Sandip Basu
Nuclear Medicine Review. Central & Eastern Europe|June 26, 2009
Revolutionary impact of PET and PET-CT on the day-to-day practice of medicine and its great potential for improving future health careSandip Basu, Abass Alavi
World Journal of Nuclear Medicine|May 30, 2017
Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE for Metastatic Neuroendocrine Tumor Occurring in Association with Multiple Endocrine Neoplasia Type 1 and Cushing's SyndromeChinna Naik, Sandip Basu
Indian Journal of Nuclear Medicine : IJNM : the Official Journal of the Society of Nuclear Medicine, India|April 13, 2018
Discordant Primary Resistance to Imatinib Mesylate in the Same Individual and Splenic Involvement in Recurring Gastric Gastrointestinal Stromal Tumors: Assessment by Fluorodeoxyglucose-Positron Emission Tomography/Computed TomographyPreeti Fargose, Sandip Basu
World Journal of Nuclear Medicine|April 14, 2021
Grade 3 metastatic neuroendocrine neoplasms of two unusual primary sites with contrasting differentiation characteristics: Dual tracer positron emission tomography and computed tomography imaging (<sup>18</sup>F-fluorodeoxyglucose and <sup>68</sup>Ga-DOTATATE) correlates and their treatment implicationsSarvesh Loharkar, Sandip Basu
Journal of Nuclear Medicine Technology|March 1, 2020
Occurrence of the Redifferentiation-Akin Phenomenon on <sup>68</sup>Ga-DOTATATE PET/CT After CAPTEM Chemotherapy in Metastatic Neuroendocrine Tumors with Intermediate MIB1 Index: What Could Be the Molecular Explanation?Priyanka Sharma, Sandip Basu
Nuclear Medicine Communications|December 5, 2019
Sub-segmentation specific paradigms for better individualized management of poorly differentiated thyroid carcinoma: can a systematic approach be evolved?Sandip Basu, Ashwini Kalshetty
Nuclear Medicine Communications|April 13, 2006
Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours?Sandip Basu, Narendra Nair
Pageof 52

Showing results (91-100 of 519) with videos related to

Sort By:
Pageof 52
Cancer Biotherapy & Radiopharmaceuticals|April 20, 2016
Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?Bhakti Basu, Sandip Basu
Journal of Nuclear Medicine Technology|April 20, 2022
Metachronous Adenocarcinoma of the Lung in the Setting of Metastatic Gastric Neuroendocrine Tumor: Value of Elucidating Discordance on Dual-Tracer PET/CT with Ki-67 IndexSarvesh Loharkar, Sandip Basu
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 5, 2019
Leveraging the power of non-radium radionuclide treatments in bone metastasesPradeep Thapa, Sandip Basu
Nuclear Medicine Review. Central & Eastern Europe|June 26, 2009
Revolutionary impact of PET and PET-CT on the day-to-day practice of medicine and its great potential for improving future health careSandip Basu, Abass Alavi
World Journal of Nuclear Medicine|May 30, 2017
Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE for Metastatic Neuroendocrine Tumor Occurring in Association with Multiple Endocrine Neoplasia Type 1 and Cushing's SyndromeChinna Naik, Sandip Basu
Indian Journal of Nuclear Medicine : IJNM : the Official Journal of the Society of Nuclear Medicine, India|April 13, 2018
Discordant Primary Resistance to Imatinib Mesylate in the Same Individual and Splenic Involvement in Recurring Gastric Gastrointestinal Stromal Tumors: Assessment by Fluorodeoxyglucose-Positron Emission Tomography/Computed TomographyPreeti Fargose, Sandip Basu
World Journal of Nuclear Medicine|April 14, 2021
Grade 3 metastatic neuroendocrine neoplasms of two unusual primary sites with contrasting differentiation characteristics: Dual tracer positron emission tomography and computed tomography imaging (<sup>18</sup>F-fluorodeoxyglucose and <sup>68</sup>Ga-DOTATATE) correlates and their treatment implicationsSarvesh Loharkar, Sandip Basu
Journal of Nuclear Medicine Technology|March 1, 2020
Occurrence of the Redifferentiation-Akin Phenomenon on <sup>68</sup>Ga-DOTATATE PET/CT After CAPTEM Chemotherapy in Metastatic Neuroendocrine Tumors with Intermediate MIB1 Index: What Could Be the Molecular Explanation?Priyanka Sharma, Sandip Basu
Nuclear Medicine Communications|December 5, 2019
Sub-segmentation specific paradigms for better individualized management of poorly differentiated thyroid carcinoma: can a systematic approach be evolved?Sandip Basu, Ashwini Kalshetty
Nuclear Medicine Communications|April 13, 2006
Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours?Sandip Basu, Narendra Nair
Pageof 52